Nelson Gray
Direttore/Membro del Consiglio presso LINC Scotland
Profilo
Nelson Gray is currently the Director at LINC Scotland and a Member at the University of St. Andrews.
He previously worked as the Chairman at Antoxis Ltd.
and as a Principal at PCB Holding Co.
Posizioni attive di Nelson Gray
| Società | Posizione | Inizio |
|---|---|---|
LINC Scotland
 LINC Scotland Financial ConglomeratesFinance LINC Scotland provides financial support services. It supports the emergence and formation of structured business angel syndicates. The company was founded in 1993 and is headquartered in Glasgow, the United Kingdom. | Direttore/Membro del Consiglio | 14/12/2009 |
| University of St. Andrews | Corporate Officer/Principal | 09/12/2009 |
Precedenti posizioni note di Nelson Gray
| Società | Posizione | Fine |
|---|---|---|
| PCB Holding Co. | Corporate Officer/Principal | - |
Antoxis Ltd.
 Antoxis Ltd. BiotechnologyHealth Technology Antoxis Ltd. designs and develops synthesis therapeutic antioxidants. The firm also develops innovative approaches for the treatment of neurodegenerative conditions, cardiovascular disease, cancer and inflammatory disorders through its mitochondrial-targeted, redox technology platform. The company was founded by Andrew Scott Johnstone and Donald Barton Mcphail in March 2005 and is headquartered in Aberdeen, the United Kingdom. | Presidente | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
| PCB Holding Co. | Finance |
LINC Scotland
LINC Scotland Financial ConglomeratesFinance LINC Scotland provides financial support services. It supports the emergence and formation of structured business angel syndicates. The company was founded in 1993 and is headquartered in Glasgow, the United Kingdom. | Finance |
Antoxis Ltd.
Antoxis Ltd. BiotechnologyHealth Technology Antoxis Ltd. designs and develops synthesis therapeutic antioxidants. The firm also develops innovative approaches for the treatment of neurodegenerative conditions, cardiovascular disease, cancer and inflammatory disorders through its mitochondrial-targeted, redox technology platform. The company was founded by Andrew Scott Johnstone and Donald Barton Mcphail in March 2005 and is headquartered in Aberdeen, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Nelson Gray
